Drug intelligence / Profile preview

AR-7732

Development stage: Preclinical
Lead developer: ARIVA Med
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

AR-7732 is a small molecule antibacterial agent belonging to the epimutilin/pleuromutilin class, currently under development by ARIVA Med. It is designed for both oral and intravenous administration to treat broad-spectrum bacterial infections. As a pleuromutilin-class antibiotic, its mechanism of action typically involves inhibiting bacterial protein synthesis by binding to the peptidyl transferase center of the 50S ribosomal subunit. AR-7732 is currently in the lead optimization and pre-clinical IND-enabling phase of development, targeting drug-resistant pathogens through its systemic activity.

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on AR-7732.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR-7732.

Explore the full profile